Avis Budget Group, Inc. (CAR)
Avis Budget (CAR) Up 3.8% Since Last Earnings Report: Can It Continue?
Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value
Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety rivaling approved autologous products. CRBU trades near net cash value, implying the market assigns minimal value to its pipeline despite RMAT designation and promising Phase 1 results. Key risks include dilution, regulatory hurdles, and competition from in vivo CAR-T, but CRBU's CRISPR chRDNA editing and leadership provide strategic advantages.
Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has appointed Dr Adrian Kilcoyne to its Scientific Advisory Board, bringing more than 20 years of oncology and immunology drug development experience to the company. Kilcoyne is currently chief medical officer at Cellectis, the French biotechnology company focused on allogeneic CAR-T therapies, which engineer a patient's immune cells to target and destroy cancer.
Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution
Kyverna Therapeutics leads CAR-T therapy for autoimmune diseases, with KYV-101 showing unprecedented efficacy in SPS and MG registrational trials. KYTX's SPS trial achieved 81% clinically meaningful improvement and all secondary endpoints, positioning the company for a BLA filing in 1H 2026. With a $279M cash runway into 2028 and strong institutional backing, KYTX is de-risked from near-term dilution and aligns with top-tier biotech investors.
Avis Budget Group Stock Declines 21.8% Since Reporting Q4 Loss
CAR shares plunge 21.8% after Q4 loss of $6.53 per share and revenue miss as Americas sales fall. The 2026 EBITDA guidance ranges from $800M to $1B.
Avis Budget Group: A Broad Q4 Miss, A Big Impairment, And A Familiar Outcome
Avis Budget Group, Inc.'s Q4 2025 results were a broad miss: $2.66B revenue vs. $2.75B Street, FY25 revenue $11.65B, missing consensus for the third straight year. The big shock was profitability with FY25 adj. EBITDA is coming in at $748M vs. the original >$1B target (later cut to $900M–$1.0B), plus near-zero Q4 EBITDA vs. $157M guided. The international segment turned around in 2025 but still remains a minor revenue contributor (23% of Q4 revenue) vs. the Americas region.
What Analyst Projections for Key Metrics Reveal About Avis Budget (CAR) Q4 Earnings
Evaluate the expected performance of Avis Budget (CAR) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Analysts Estimate Avis Budget Group (CAR) to Report a Decline in Earnings: What to Look Out for
Avis Budget (CAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAR Group Limited (CSXXY) Q2 2026 Earnings Call Transcript
CAR Group Limited (CSXXY) Q2 2026 Earnings Call Transcript
Reasons Why You Should Retain Avis Budget Stock in Your Portfolio
CAR's rental-led growth shines as Q4 2025 revenues and earnings are set to rise, backed by fleet efficiency, tech upgrades and the premium Avis First launch.
Why Is Avis Budget (CAR) Down 8% Since Last Earnings Report?
Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?
Avis Budget Stock Declines 11% Despite Reporting Q3 Earnings Beat
CAR's third-quarter 2025 earnings and revenues top estimates, yet the stock slides 11% as investors react to mixed segmental results.
